These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17379968)

  • 41. Sequential use of biologic therapy in rheumatoid arthritis.
    Buch MH
    Curr Opin Rheumatol; 2010 May; 22(3):321-9. PubMed ID: 20190641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Five-year data from the REFLEX study: a different interpretation.
    Abeles AM
    J Rheumatol; 2013 May; 40(5):732. PubMed ID: 23637377
    [No Abstract]   [Full Text] [Related]  

  • 43. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab.
    Gelinck LB; Teng YK; Rimmelzwaan GF; van den Bemt BJ; Kroon FP; van Laar JM
    Ann Rheum Dis; 2007 Oct; 66(10):1402-3. PubMed ID: 17881666
    [No Abstract]   [Full Text] [Related]  

  • 44. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 45. [TNF antagonists in therapy of rheumatoid arthritis].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
    [No Abstract]   [Full Text] [Related]  

  • 46. Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α.
    Onishi S; Yoshio T; Nagashima T; Minota S
    Mod Rheumatol; 2010 Oct; 20(5):528-30. PubMed ID: 20458607
    [No Abstract]   [Full Text] [Related]  

  • 47. Tumour necrosis factor blockade in rheumatoid arthritis.
    Breedveld FC
    Clin Med (Lond); 2001; 1(2):107-9. PubMed ID: 11333452
    [No Abstract]   [Full Text] [Related]  

  • 48. New therapies for treatment of rheumatoid arthritis.
    Smolen JS; Aletaha D; Koeller M; Weisman MH; Emery P
    Lancet; 2007 Dec; 370(9602):1861-74. PubMed ID: 17570481
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The as-yet unfulfilled promise of p38 MAPK inhibitors.
    Sweeney SE
    Nat Rev Rheumatol; 2009 Sep; 5(9):475-7. PubMed ID: 19710669
    [No Abstract]   [Full Text] [Related]  

  • 50. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL; Silman AJ
    J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
    [No Abstract]   [Full Text] [Related]  

  • 51. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
    Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
    J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Etanercept for therapy of rheumatoid arthritis].
    Miyasaka N
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():521-5. PubMed ID: 15799411
    [No Abstract]   [Full Text] [Related]  

  • 53. Plantar pustulosis during rituximab therapy for rheumatoid arthritis.
    Brunasso AM; Massone C
    J Am Acad Dermatol; 2012 Oct; 67(4):e148-50. PubMed ID: 22980273
    [No Abstract]   [Full Text] [Related]  

  • 54. Rituximab therapy for flare-up of rheumatoid arthritis after total knee replacement surgery.
    Mirza R; Ishaq S; Khan MO; Memon A
    J Pak Med Assoc; 2012 Oct; 62(10):1120-3. PubMed ID: 23866466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Anti-cytokine therapy for connective tissue disease].
    Hayashi T; Goto D; Sumida T
    Nihon Rinsho; 2005 May; 63 Suppl 5():233-9. PubMed ID: 15954355
    [No Abstract]   [Full Text] [Related]  

  • 58. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.
    Narvaez J; Díaz-Torné C; Ruiz JM; Hernandez MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
    Clin Exp Rheumatol; 2011; 29(6):991-7. PubMed ID: 22133052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.
    Brown DS; Belfield AJ; Brown GR; Campbell D; Foubister A; Masters DJ; Pike KG; Snelson WL; Wells SL
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5383-7. PubMed ID: 15454231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ; Hyrich KL
    BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.